第十一届董事会2025年第四次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：000915 证券简称：华特达因 公告编号：2025-021 山东华特达因健康股份有限公司 山东华特达因健康股份有限公司第十一届董事会于 2025 年 4 月 27 日以电子邮件形式发出召开 2025 年第四次临时会议的通知，并于 2025 年 4 月 29 日以通讯方式召开会议。会议应参加董事 8 名，实际 参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法 律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关于股 东临时提案不予提交股东会审议的议案"。 具 体 内 容 详 见 公 司 同 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《董事会关于对股东临时提案 不予提交股东会审议事项说明的公告》。 （三）备查文件 经与会董事签字并加盖董事会印章的董事会决议； 特此公告 山东华特达因健康股份有限公司董事会 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-020 山东华特达因健康股份有限公司 董事会关于对股东临时提案不予提交股东会审议事项 说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第十一届董事会第三次会议，决定于 2025 年 5 月 13 日召开公司 2024 年年度股东会，并于 2025 年 4 月 19 日发布《关于 召开 2024 年年度股东会的通知》。 近日，公司收到持股 3%以上股东尹俊涛先生发来的《关于增加股 东大会临时提案的函》，尹俊涛先生提请增加"关于制定《存量资金 分级管理与使用办法》的提案"至公司 2024 年年度股东会审议。近 年来，公司在股东的关注和支持下，积极聚焦主业，加强经营管理， 在业绩稳定增长的同时，积极维护股东利益加大分红回报股东，2024 年中期和年度合计现金分红金额达到 2024 年度公司归属母公司股东 扣除非经常性损益后净利润的 119%。公司董事会对上述临时提案进 行了审议并作出决议，现将相关事项公告如 ...

北 京 德 恒 （ 济 南 ） 律 师 事 务 所 DeHeng Law Offices（Jinan） Building 2, Yinfeng Science and Technology Park, No. 567 Shuntai North Road, Hi-Tech Zone, Jinan, Shandong, China 中国 山东省济南市高新区舜泰北路 567 号银丰科技公 园 2 号楼 致：山东华特达因健康股份有限公司 山东华特达因健康股份有限公司（简称"华特达因"或"贵公司"或"公司"）董 事会在 2024 年年度股东会召开前，收到股东尹俊涛提交的一份《关于制定<存量资金分 级管理与使用办法>》的临时提案。董事会依法审议后认为股东尹俊涛提交的临时提案 不符合提交股东会审议的条件，并作出不予提交股东会审议的决议。 北京德恒（济南）律师事务所（简称"德恒"或"本所"）接受华特达因的委托， 就华特达因董事会对股东尹俊涛临时提案不予提交股东会审议事项进行合法合规性审 查，并出具法律意见。本所律师根据《中华人民共和国公司法》（简称"《公司法》"） 《中华人民共和国证券法》（简称"《证券法》"）《中华人民共 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% within the next six months [5][17]. Core Insights - The company reported a revenue of 616 million yuan for Q1 2025, reflecting a year-on-year increase of 7.78%, and a net profit of 182 million yuan, up 8.13% year-on-year [2]. - The gross margin improved to 86.31%, an increase of 1.42 percentage points year-on-year, while the net profit margin reached 56.12%, up 0.4 percentage points [2]. - The company is expanding its core product offerings and enhancing its market position in the children's health sector, particularly with its flagship product, the Vitamin AD drops [4]. Financial Performance - The company’s operating expenses for Q1 2025 were optimized, with sales, management, and R&D expense ratios at 15.77%, 2.75%, and 2.35% respectively, showing year-on-year changes of +0.2, -1.02, and +0.15 percentage points [3]. - The financial forecast estimates revenues of 2.37 billion yuan, 2.64 billion yuan, and 2.94 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 11% for both 2025 and 2026, and 12% for 2027 [5][7]. Product Development and Market Strategy - The company is focusing on expanding its product matrix to meet diverse health needs for children, including new product lines targeting skin health [4]. - Strategic partnerships, such as the collaboration with Duomeikang Bio, are aimed at exploring new opportunities in children's skin health [4]. - The company is enhancing its marketing strategies and channel development, particularly in retail and e-commerce, to promote its products effectively [4].

Financial Performance - The company reported a total revenue of 616 million yuan for Q1 2025, representing a year-on-year increase of 7.78% [1] - The net profit attributable to shareholders reached 182 million yuan, up 8.13% year-on-year [1] - The gross margin improved to 86.31%, an increase of 1.68% compared to the previous year, while the net margin rose to 56.12%, up 0.71% [1] Key Financial Metrics - The company's operating expenses, including sales, management, and financial costs, totaled 109 million yuan, accounting for 17.7% of revenue, which is a 0.93% increase year-on-year [1] - Earnings per share (EPS) increased to 0.78 yuan, reflecting an 8.33% year-on-year growth [1] - The cash flow from operating activities per share decreased significantly by 76.42% to 0.23 yuan [1] Business Model and Market Position - The company has a strong return on invested capital (ROIC) of 21.97% and a net profit margin of 47.13%, indicating high value addition in its products or services [3] - The company has a healthy cash asset position and has cumulatively raised 140 million yuan in financing while distributing 1.346 billion yuan in dividends since its listing [3] - The collaboration with China Resources is aimed at promoting vitamin D supplements, enhancing market penetration and resource sharing [5] Fund Holdings - The largest fund holding in the company is by Tianzhi New Consumption Mixed Fund, which holds 13,200 shares, marking a new entry into the top ten holdings [4] - The fund's current scale is 0.17 billion yuan, with a recent net value of 0.8065, reflecting a decline of 0.74% from the previous trading day [4]

证券代码：000915 证券简称：华特达因 公告编号：2025-019 山东华特达因健康股份有限公司 关于召开2024年年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2024 年年度股东会 2.会议召集人：公司董事会 3.会议召开的合法、合规性：董事会认为本次会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4.会议召开的日期、时间： 4.1 现场会议召开时间：2025 年 5 月 13 日下午 14:30 4.2 网络投票时间：2025 年 5 月 13 日 4.2.1 通过深圳证券交易所交易系统投票的时间为 2025 年 5 月 13 日上午 9:15－9:25，9:30－11:30，下午 13:00－15:00； 4.2.2 通过深圳证券交易所互联网系统 (http://wltp.cninfo.com.cn) 投票时间为 2025 年 5 月 13 日 09:15 至 2025 年 5 月 13 日 15:00 期间 的任意时间。 5.会议的召开方式：本次股东会采取 ...

山东华特达因健康股份有限公司 第十一届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东华特达因健康股份有限公司第十一届监事会于 2025 年 4 月 7 日以电子邮件形式发出召开第三次会议的通知，并于 2025 年 4 月 17 日在公司会议室召开会议。会议应参加监事 5 名，实际参加监事 5 名。会议由监事会主席沈宝杰先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 股票代码：000915 股票简称：华特达因 公告编号：2025-018 经审核，监事会认为董事会编制和审议《公司 2025 年第一季度 报告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容 真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记 载、误导性陈述或者重大遗漏。 （三）备查文件 经与会监事签字并加盖监事会印章的监事会决议。 特此公告 山东华特达因健康股份有限公司监事会 二、监事会会议审议情况 以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年第一季度报告》并发表如下审核意见 ...

山东华特达因健康股份有限公司 证券代码：000915 证券简称：华特达因 公告编号：2025-015 第十一届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 于召开公司 2024 年年度股东会的议案》，决定于 2025 年 5 月 13 日召 开公司 2024 年年度股东会。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 特此公告 1.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年第一季度报告》。 2.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《关 于聘请 2025 年度会计师事务所的议案》，提交公司 2024 年年度股东 会审议。 聘请致同会计师事务所（特殊普通合伙）为公司 2025 年度的财 务审计及内部控制审计机构，费用 45 万元，其中财务审计 37 万元， 内部控制审计 8 万元。 本议案提交董事会前，已经第十一届董事会审计委员会第三次会 议审议通过。 3.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《关 山东华特达因健 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 616,291,375.97, representing a 7.78% increase compared to CNY 571,800,385.84 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 was CNY 182,345,987.39, an increase of 8.13% from CNY 168,635,228.17 year-over-year[4] - The net profit after deducting non-recurring gains and losses was CNY 179,265,608.33, reflecting a 10.79% increase compared to CNY 161,806,595.60 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥616,291,375.97, an increase of 7.9% compared to ¥571,800,385.84 in Q1 2024[15] - Operating profit for the period was ¥406,682,555.92, up from ¥375,477,072.98, reflecting a growth of 8.3%[15] - Net profit attributable to the parent company was ¥182,345,987.39, compared to ¥168,635,228.17 in the previous year, marking an increase of 8.5%[16] - The basic earnings per share for the period was ¥0.78, up from ¥0.72, representing an increase of 8.3%[16] Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 76.42%, amounting to CNY 54,158,675.30, down from CNY 229,718,341.80 in the same quarter last year[4] - Cash inflow from operating activities was ¥583,519,973.25, down from ¥665,941,990.00, a decrease of 12.4%[17] - The net cash flow from operating activities was $54,158,675.30, a decrease of 76.4% compared to $229,718,341.80 in the previous period[18] - Cash outflow from investing activities totaled $900,040,021.22, an increase of 22.1% from $736,924,140.36 in the prior period[18] - The net cash flow from investing activities was -$146,958,058.49, contrasting with a positive cash flow of $6,710,675.52 previously[18] - The cash inflow from investment activities was $753,081,962.73, slightly up from $743,634,815.88 in the previous period[18] - The company reported a net increase in cash and cash equivalents of -$92,799,383.19, compared to an increase of $2,790,962.32 in the prior period[18] Assets and Liabilities - Total assets at the end of Q1 2025 reached CNY 5,156,848,902.20, a 4.58% increase from CNY 4,930,936,591.73 at the end of the previous year[4] - Total assets increased to ¥5,156,848,902.20 from ¥4,930,936,591.73, representing a growth of 4.6%[14] - Total liabilities rose to ¥902,978,082.34, up from ¥518,499,753.28, indicating a significant increase of 74.0%[14] - The company's total current assets as of March 31, 2025, amount to CNY 3,746,489,988.74, an increase from CNY 3,510,737,250.04 at the beginning of the period[12] - The total non-current assets are valued at CNY 1,470,000,000.00, with fixed assets at CNY 840,028,196.41[12] Shareholder Equity and Structure - Shareholders' equity attributable to the parent company increased by 6.26% to CNY 3,093,997,428.26 from CNY 2,911,651,440.88 at the end of the last year[4] - The company's total equity attributable to shareholders reached ¥3,093,997,428.26, compared to ¥2,911,651,440.88, an increase of 6.3%[14] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of the shares, totaling 51,544,340 shares[10] - There are no significant changes in the shareholder structure or related party transactions reported[10] Other Financial Metrics - The weighted average return on equity rose to 6.07%, an increase of 0.57 percentage points from 5.50% in the previous year[4] - The company reported a significant increase in accounts receivable by 55.02%, totaling CNY 384,123,102.63 due to an increase in bank acceptance bills held[7] - Prepayments increased by 115.04% to CNY 73,973,722.89, attributed to higher advance payments to suppliers[7] - Other payables surged by 605.54% to CNY 522,918,269.00, primarily due to increased dividends payable from the subsidiary Dain Pharmaceutical[7] - Research and development expenses increased to ¥14,462,161.65 from ¥12,559,406.43, reflecting a growth of 15.2%[15] Audit and Reporting - The first quarter report was not audited, indicating a potential area for further scrutiny in financial reporting[19]

Core Insights - The company reported a revenue of 616 million yuan for the first quarter of 2025, representing a year-on-year growth of 7.78% [1] - The net profit for the same period was 182 million yuan, showing an increase of 8.13% compared to the previous year [1]